Bio-Rad Labs (BIO) Tops Q2 EPS by $1.10, Misses on Revenue; Offers Q3 Guidance
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $382.41 +0.89%
EPS Growth %: -1.3%
Financial Fact:
Foreign exchange losses, net: 1.24M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -1.3%
Financial Fact:
Foreign exchange losses, net: 1.24M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.11, $1.10 better than the analyst estimate of $2.01. Revenue for the quarter came in at $638.5 million versus the consensus estimate of $645.79 million.
GUIDANCE:
Bio-Rad Labs sees Q3 2024 revenue of $638.5-681.1 million, versus the consensus of $661 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Stryker (SYK) PT Lowered to $385 at Canaccord
- Boeing wins $112m contract for Saudi F-15 training program
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
